Abstract Submission

Abstract Submission

The top platform for presenting your research is at the ESO-WSO Conference

Start here
  • Abstract Submission Deadline for Ongoing Trials: Tuesday, 22 September 2020, midnight CET (23:59).
  • Late-Breaking Abstract Submission Deadline: Tuesday, 22 September 2020, midnight CET (23:59).

Key Dates

Abstract Submission Opens September 2019
Abstract Submission Deadline For all topics except ongoing trials: Wednesday, 15 January 2020, midnight CET (23:59)

For ongoing trials: Tuesday, 22 September 2020, midnight CET (23:59)

*There will not be an extension to this deadline

Abstract Notification* Early March 2020
Late-Breaking Abstract Submission Opens Monday, 22 June 2020
Late-Breaking Abstract Submission Deadline 22 September 2020, midnight CET (23:59).
Late-Breaking Abstract Submission Notification*  7-8 October 2020

*Note all efforts are made to send notification by the planned date. Should there be any delays with the selection process, revised date will be posted here.


The ongoing trials topic – is only for proposed posters that will describe the design and/or progress of ongoing trials – trials that will not have closed in time to present results at ESO-WSO 2020, (November 7-9).

Note: Abstracts describing as yet unfinished trials which will complete in time to present results at ESO-WSO 2020 must be submitted as placeholder abstracts for late-breaking results in the main abstract submission, under the most relevant trial topic by the general deadline of January 15th. You will find an option to indicate that your submission is a placeholder abstract. A placeholder abstract should describe the trial and the analyses that will be available. You can update your abstract with results during the late-breaking submission window from 22 June 2020 to 22 September 2020. If you anticipate having a late-breaking trial, you must submit a placeholder abstract by January 15th. This will assist the conference committee in reserving a suitable slot on the program. View Abstract Topics.

Late-Breaking Abstracts

Only Clinical Trials topics will be available during this submission.

  • Clinical Trial Results – Acute Management – Neither Thrombolysis Nor Thrombectomy
  • Clinical Trial Results – Acute Management – Thrombolysis Or Thrombectomy
  • Clinical Trial Results – Prevention
  • Clinical Trial Results – Rehabilitation & Recovery

The late-breaking abstract deadline is not an extension of the abstract submission deadline.

The content of the abstract should not have been previously published or presented at national or international meetings prior to ESO-WSO 2020. Late-breaking abstracts should describe either:

  • Prospective studies for which results were not known at the initial ESO-WSO 2020 abstract deadline but will complete in time to present results at ESO-WSO 2020
  • Important translational studies with emerging results

Rules for Submission

Please read the submission rules before submitting an abstract.

  • Abstracts must be submitted online via the website only. Abstracts submitted by email will not be accepted.
  • Presentation Type: Abstracts may be submitted for oral or poster presentation.
    The Scientific Abstracts Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.
  • Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
  • Limitations:
  • The same person may submit up to 5 abstracts regardless of presenting author.
  • The same person may serve as a presenting author on up to 5 abstracts.
  • Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees will be scheduled for presentation and included for publication.
  • Submission of an abstract acknowledges your acceptance for the abstract to be published in the official conference publications.
  • The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
  • Accepted abstracts submitted during the regular submission (January 15 deadline), will be published online in the International Journal of Stroke. Ongoing Trials and Late-Breaking abstracts will not be published in the Journal.
  • Previously Presented/Published Policy: Abstracts that have been previously presented or Published may not be submitted.
  • Abstracts must be submitted in English.
    All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university-specific publications office (or another similar facility) or by a copy editor, prior to submission.
  • Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.
  • Instructions for preparation of presentations will be made available on the conference website.
  • Publication Embargo: ESO-WSO 2020 has an embargo policy on all abstracts submitted to the conference. The embargo will be lifted on November 7, 2020.


Guidelines for Submission

​Before you begin, please prepare the following information:

  • Presenting author’s contact details:
    – Full first and family name(s)
    – Email address
    – Affiliation details: department, institution / hospital, city, state (if relevant), country
    – Phone number
  • Author and co-authors’ details
  • Preferred Presentation type: Oral/Poster presentation/ Poster Viewing
  • Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
  • Abstract text – limited to 250 words including acknowledgements. Please note word count is affected when tables are included.
  • Abstract topic– select the abstract topic per the list of topics
  • Images– The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format.
  • Abstracts should clearly state:
    • Background and aims
    • Methods
    • Results
    • Conclusions
  • Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
  • Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
  • Submissions may not contain patient names, hospital ID numbers or other identifying information.
  • The submission form allows you to store your abstract as a DRAFT until the deadline. After the deadline if not submitted, drafts will be deleted.
  • Click on the SUBMIT button at the end of the process in order to submit your abstract. Changes will not be possible to your abstract after it is submitted.
  • You will receive an abstract ID number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
  • Please contact us if you have not received confirmation that your abstract has been submitted.
  • Please do not submit multiple copies of the same abstract.


Abstract Submitters’ Declaration

During abstract submission you will be asked to confirm that you agree to the following:

  1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published as submitted.
  2. Submission of the abstract constitutes the consent of all authors to publication (e.g. Conference website, programs, other promotions, etc.)
  3. The Abstract Submitter warrants and represents that no part of the information and content provided by him/her (Hereafter: the “Content“) to ESO-WSO 2020and Kenes International (Hereafter: the “Organizers“), nor the publication of any such Content by the Organizers, on the internet or otherwise infringes any third party rights, including but not limited to privacy rights and/or intellectual property rights.
  4. The Abstract Submitter grants the Organisers a copyright license to reproduce, publish, translate, distribute, and display the text of the Content on a royalty-free, perpetual, irrevocable nonexclusive basis.
  5. I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on the abstract correspondence.
  6. I understand that the presenting author must be a registered participant.
  7. The Organizers reserve the right to remove from publication and/or presentation an abstract which does not comply with the above.
  8. I understand that I must select a specific Theme, Topic and/or Sub-Topic for my abstract allocation.  Although the Committee will work hard to honour this selection, this cannot be guaranteed.  The Committee reserves the right to change the Theme, Topic or Sub-Topic under which the abstract was originally submitted.


Scientific Abstracts committee

  • Alexander Thiel – Canada, Chair
  • Alistair Webb -UK, Chair
  • Eivind Berge – Norway
  • Geert Jan Biessels – the Netherlands
  • Bruce Campbell – Australia
  • Valery Feigin – New Zealand
  • Pooja Khatri-USA